Dual targeting of salt inducible kinases and csf1r uncouples bone formation and bone resorption

Cheng Chia Tang, Christian D.Castro Andrade, Maureen J. O’meara, Sung Hee Yoon, Tadatoshi Sato, Daniel J. Brooks, Mary L. Bouxsein, Janaina da Silva Martins, Jinhua Wang, Nathanael S. Gray, Barbara Misof, Paul Roschger, Stephane Boulin, Klaus Klaushofer, Annegreet Velduis-Vlug, Yosta Vegting, Clifford J. Rosen, Daniel O’connell, Thomas B. Sundberg, Ramnik J. XavierPeter Ung, Avner Schlessinger, Henry M. Kronenberg, Rebecca Berdeaux, Marc Foretz, Marc N. Wein

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Bone formation and resorption are typically coupled, such that the efficacy of anabolic osteoporosis treatments may be limited by bone destruction. The multi-kinase inhibitor YKL-05–099 potently inhibits salt inducible kinases (SIKs) and may represent a promising new class of bone anabolic agents. Here, we report that YKL-05–099 increases bone formation in hypogonadal female mice without increasing bone resorption. Postnatal mice with inducible, global deletion of SIK2 and SIK3 show increased bone mass, increased bone formation, and, distinct from the effects of YKL-05–099, increased bone resorption. No cell-intrinsic role of SIKs in osteoclasts was noted. In addition to blocking SIKs, YKL-05–099 also binds and inhibits CSF1R, the receptor for the osteoclastogenic cytokine M-CSF. Modeling reveals that YKL-05–099 binds to SIK2 and CSF1R in a similar manner. Dual targeting of SIK2/3 and CSF1R induces bone formation without concomitantly increasing bone resorption and thereby may overcome limitations of most current anabolic osteoporosis therapies.

Original languageEnglish
Article numbere67772
StatePublished - Jun 2021


Dive into the research topics of 'Dual targeting of salt inducible kinases and csf1r uncouples bone formation and bone resorption'. Together they form a unique fingerprint.

Cite this